Nondisjunction and Aneuploidy
A woman in her late thirties undergoes prenatal screening. The karyotype comes back with three copies of chromosome 21 instead of two. Nothing in her lifestyle caused this. Nothing about the DNA sequence itself is abnormal — every gene is a perfectly normal human gene. The problem is purely one of chromosome counting. It was a failure that occurred during a single cell division decades earlier. This happened before she was even born, inside cells that would become her egg. This is nondisjunction. Its consequence — aneuploidy, an abnormal chromosome number — is one of the most common and consequential kinds of mutation in human biology. Aneuploidy matters because chromosome number is not a cosmetic detail of the genome. It is a dosage problem. Genes are read out, transcribed, and translated in proportion to how many copies of the template DNA a cell has. Add or remove a whole chromosome, and hundreds or thousands of genes suddenly have the wrong dosage. This happens simultaneously, throwing off the stoichiometry of entire protein complexes and regulatory networks. This is why aneuploidy is so much more devastating, on average, than a single point mutation. It is also why it is the leading identifiable cause of pregnancy loss in humans. It is implicated in more than half of first-trimester spontaneous abortions. The big picture connects two things students often treat separately. These are the elegant choreography of meiosis and the blunt, quantitative reality of clinical genetics. Understanding nondisjunction requires knowing exactly which meiotic step failed. Meiosis I and Meiosis II nondisjunction leave different molecular fingerprints. They also produce different mixtures of aneuploid gametes. It also requires knowing why some aneuploidies are compatible with live birth. These include trisomy 21, trisomy 18, trisomy 13, and the sex chromosome aneuploidies. Others, like trisomy for most autosomes, are not. This article works through the mechanism of nondisjunction step by step. It distinguishes MI from MII failure, and sister-chromatid nondisjunction from homolog nondisjunction. It presents the classical evidence — Calvin Bridges' Drosophila experiments. These experiments first proved the chromosome theory of inheritance, using nondisjunction as the tool. It pairs this with modern human data on maternal age and trisomy risk. It works two quantitative examples and addresses common misconceptions. It closes with the clinical and reproductive-technology stakes of getting chromosome counting right.
- Nondisjunction is the failure of homologous chromosomes (Meiosis I) or sister chromatids (Meiosis II, or mitosis) to separate properly, producing gametes or cells with too many or too few chromosomes.
- Aneuploidy — trisomy (2n+1) or monosomy (2n−1) — results when an aneuploid gamete fuses with a normal one at fertilization.
- MI nondisjunction sends both homologs to one pole; MII nondisjunction sends both sister chromatids of one homolog to one pole — they produce distinguishable patterns of heterozygosity at centromere-linked markers.
- Calvin Bridges' 1913–1916 Drosophila nondisjunction experiments provided direct, decisive proof that genes physically reside on chromosomes.
- In humans, autosomal trisomies 21, 18, and 13 and the sex-chromosome aneuploidies (XXY, XYY, XXX, XO) are the surviving classes; most other aneuploidies are lethal in utero.
- Maternal age strongly increases the risk of trisomy because human oocytes arrest for years to decades in meiotic prophase I, during which cohesin holding chromosomes together degrades.
Nondisjunction is a failure of chromosome segregation, not of DNA sequence, so aneuploidy is fundamentally a dosage disease — the wrong number of otherwise normal genes.
The core idea
Nondisjunction is the failure of paired chromosomes to separate properly during cell division, so that both members of a pair travel to the same pole instead of one going to each. It can happen in mitosis, but it is most consequential — and most studied — in meiosis, where it directly produces gametes with an abnormal chromosome number. When such a gamete fuses with a normal gamete at fertilization, the resulting zygote is aneuploid: it has one chromosome too many (trisomy, 2n+1) or one too few (monosomy, 2n−1), rather than the normal diploid balance of exactly two copies of every chromosome. Aneuploidy must be distinguished from <a class="wiki-link" href="/wiki/bio-genet-polyploidy" data-track="wiki_article.body.wiki_link">Polyploidy</a>, in which entire extra sets of chromosomes are added (3n, 4n), and from structural chromosome mutations such as <a class="wiki-link" href="/wiki/bio-genet-translocations" data-track="wiki_article.body.wiki_link">Translocations</a>, in which pieces of chromosomes are exchanged or relocated without any change in total gene copy number. Aneuploidy changes the number of whole or nearly-whole chromosomes; the DNA sequence on each chromosome is normal. What is abnormal is the dose — the ratio of gene copies to the rest of the genome. Because most genes' products must be produced in tightly regulated, stoichiometric amounts relative to their partners in protein complexes and regulatory circuits, a 50% increase or decrease in the copy number of hundreds of genes at once is a large physiological perturbation even though no gene has mutated. Nondisjunction can occur at either meiotic division, and the two failures are mechanistically distinct. Meiosis I (MI) nondisjunction is a failure of homologous chromosomes to separate; both homologs (each still consisting of two sister chromatids) go to the same pole. Meiosis II (MII) nondisjunction is a failure of sister chromatids to separate after the homologs have already correctly segregated at MI; both sister chromatids of one chromosome go to the same pole. Both routes can generate a gamete with an extra or missing chromosome, but they leave different genetic signatures at loci near the centromere — a distinction that is not merely academic, since it is used diagnostically to determine which parental meiotic division was the origin of a trisomy in human genetic counseling.
Mechanism
Normal segregation, briefly reviewed. In meiosis I, homologous chromosomes pair (synapse) and undergo crossing over, then are pulled toward opposite poles by microtubules attached to their kinetochores, held apart by the release of cohesin along chromosome arms while cohesin at the centromere is protected. In meiosis II, which resembles mitosis, sister chromatids — held together only at centromeric cohesin — separate and go to opposite poles. Proper segregation at both steps depends on: 1. Correct synapsis and crossing over at MI, which physically links homologs via chiasmata and is normally required for the spindle checkpoint to allow anaphase I. 2. Bi-orientation: kinetochores of the two homologs (at MI) or two sisters (at MII) must attach to microtubules from opposite spindle poles. 3. Cohesin integrity: arm cohesin must persist until anaphase I (to resist the pulling forces and allow proper tension-sensing) and centromeric cohesin must persist until anaphase II. 4. The spindle assembly checkpoint (SAC), which delays anaphase until all kinetochores are properly attached and under tension.
How nondisjunction happens. Several distinct molecular failures converge on the same outcome:
- Achiasmate homologs. If a pair of homologs fails to cross over (or crosses over too near a chromosome end), they lack the chiasma that normally holds them together and orients them on the spindle. Without this physical tether, the homologs can attach randomly, both facing the same pole, and segregate together at MI — pure MI nondisjunction.
- Premature loss of cohesin. Centromeric cohesin, protected during MI by the protein shugoshin (which recruits the phosphatase PP2A to keep cohesin dephosphorylated and resistant to separase), can degrade prematurely — a process worsened by prolonged meiotic arrest. If sister chromatids lose their cohesive glue before MII, they may separate precociously or fail to properly bi-orient, causing MII nondisjunction or, in some models, "reverse segregation" in which the two chromatids of a homolog separate at MI instead of MII.
- Checkpoint failure. If the SAC does not detect a mal-oriented or unattached kinetochore, anaphase proceeds anyway, "assisting" missegregation rather than preventing it.
- Merotelic attachment / spindle defects. A single kinetochore attaching to microtubules from both poles can drag a chromosome to the wrong side regardless of cohesion status; this is a significant contributor in mitotic nondisjunction and cancer aneuploidy.
MI versus MII: what each produces. In MI nondisjunction, both homologs move to the same pole (each still as a pair of sister chromatids); MII then proceeds normally, splitting sisters apart. This produces two gametes with n+1 (both homologs of the affected chromosome, non-identical at the centromere because of crossing over) and two gametes with n−1 (missing that chromosome entirely). In MII nondisjunction, MI is normal, but at MII one pole receives both sister chromatids of one chromosome (which are identical at the centromere, having not recombined between themselves) while the other pole gets none for that chromosome; the other two gametes from that same MI division are normal (n). A key experimental and diagnostic consequence: MI-derived trisomies show heterozygosity for markers very close to the centromere (because both homologs, having recombined, are present and different there), while MII-derived trisomies tend to show homozygosity at the centromere (because two identical sister chromatids are present). This distinction is used in molecular studies of human trisomies to trace the parental cell division of origin.
From gamete to zygote. An n+1 gamete fertilized by a normal n gamete gives a 2n+1 trisomic zygote; an n−1 gamete fertilized normally gives a 2n−1 monosomic zygote. Whether that zygote survives to be born, and with what phenotype, depends heavily on which chromosome is involved and how gene-dense and dosage-sensitive it is.
What happens after fertilization: dosage stress. Once a trisomic or monosomic zygote forms, the phenotype arises largely from gene dosage imbalance. Most genes on the extra (or missing) chromosome are transcribed roughly in proportion to their copy number, so a trisomic cell makes about 1.5-fold the normal amount of mRNA and protein for hundreds to thousands of genes simultaneously, while a monosomic cell makes about half. Because so many cellular pathways depend on precise stoichiometric ratios between interacting proteins — for instance, subunits of the same protein complex — this broad, simultaneous imbalance disrupts proteostasis, imposes chronic stress on protein-folding machinery, and skews signaling network outputs. This is a key reason that autosomal monosomy in humans is essentially always lethal very early in development (loss of half the products of an entire chromosome's worth of genes is catastrophic), whereas some autosomal trisomies (a 1.5× excess) can, for gene-poor chromosomes like 21, permit survival to birth and beyond.
The evidence
Calvin Bridges and the direct proof of the chromosome theory (1913–1916). By the early 1910s, Thomas Hunt Morgan's group had shown that genes such as white eye color in Drosophila melanogaster segregate in patterns that parallel the behavior of the X chromosome — strong circumstantial evidence that genes are physically located on chromosomes. But correlation between inheritance patterns and chromosome behavior was not yet direct proof; a skeptic could argue the parallel was coincidental. Calvin Bridges, working in Morgan's lab, supplied the decisive experiment. Bridges crossed white-eyed females (genotype X^w X^w) to red-eyed (wild-type) males (X^+ Y). The ordinary Mendelian prediction, given X-linked inheritance, is that all daughters should be red-eyed (X^+ X^w) and all sons white-eyed (X^w Y), because sons receive their only X from the mother. Bridges observed that the vast majority of offspring followed this rule — but at low but reproducible frequency (roughly 1 in 2,000), exceptional offspring appeared: white-eyed daughters and red-eyed sons, the opposite of what standard X-linkage predicts. Bridges hypothesized that these exceptions arose from nondisjunction of the X chromosomes in the mother, occurring during meiosis in the white-eyed female parent. If the two X^w chromosomes failed to separate at meiosis I, an exceptional egg could be produced carrying both maternal X^w chromosomes (or, from a different missegregation, no X at all). Fertilization of an XX-carrying egg (X^w X^w) by a normal Y-bearing sperm would yield an XXY (X^w X^w Y) white-eyed daughter; fertilization of a no-X egg by an X^+-bearing sperm would yield an X^+O (X^+ 0) red-eyed son (Drosophila males with a single X and no Y, X0, are viable, unlike in mammals). The decisive test was cytological. Bridges predicted that if his hypothesis were correct, the exceptional white-eyed daughters should carry three sex chromosomes: XXY, and this could be checked directly under the microscope because D. melanogaster has a large, morphologically distinctive Y chromosome. Bridges examined the chromosomes of these exceptional females and found exactly the predicted XXY constitution — a visible extra chromosome, present precisely in the flies whose genetics predicted it, and absent in flies whose genetics predicted a normal complement. He further showed exceptional males were X0, lacking a Y entirely, again matching cytological prediction. This was the key piece of evidence historically: a specific, unusual genetic outcome (an exceptional class of offspring, at a specific low frequency) was predicted to correspond to a specific, unusual, and independently visible chromosomal abnormality — and the chromosome count matched the genetic prediction exactly. Because the physical chromosome complement and the pattern of gene transmission were shown to co-vary in this precise, testable way, Bridges' 1916 paper ("Non-disjunction as proof of the chromosome theory of heredity") is regarded as the most direct confirmation that genes are carried on chromosomes, converting the chromosome theory of heredity from a compelling correlation into an established fact.
Modern human cytogenetic evidence: maternal age and trisomy. A second, independent body of evidence — accumulated from large-scale karyotyping of spontaneous abortions and live births beginning in the mid-20th century (following Jérôme Lejeune's 1959 discovery that Down syndrome is trisomy 21) — established that the risk of autosomal trisomy in humans rises sharply with maternal age, and molecular marker studies (using polymorphic centromeric DNA markers) later showed that the great majority of these trisomies originate from nondisjunction in the mother's meiosis I, consistent with the fact that human oocytes are arrested in meiotic prophase I for years to decades (from before birth until ovulation), during which cohesin proteins holding chromosomes together gradually degrade without being replenished, weakening the physical tethers needed for accurate MI segregation.
| Maternal age | Approx. risk of Down syndrome (trisomy 21) at birth |
|---|---|
| 20 | ~1 in 1,500 |
| 30 | ~1 in 900 |
| 35 | ~1 in 350 |
| 40 | ~1 in 100 |
| 45 | ~1 in 30 |
These figures (from large-scale population cytogenetic studies) are approximate and vary by dataset, but the trend — a roughly exponential rise after age 35 — is one of the most robust dose-response relationships in human genetics, and it is a direct epidemiological signature of the cohesin-decay mechanism of MI nondisjunction.
Worked examples
Example 1 — Tracing a trisomy to MI or MII using centromeric markers. A geneticist studies a family in which a child has trisomy 21. The mother is heterozygous at a DNA marker locus very close to the centromere of chromosome 21: allele A on one homolog, allele B on the other. The father is homozygous C/C at this locus (irrelevant to distinguishing maternal origin). The trisomic child's three copies of chromosome 21 are genotyped at this marker.
- If the child is A/B/C — carrying both maternal alleles (A and B) plus the paternal allele (C) — this shows that both maternal homologs, which differ at this near-centromeric marker because they underwent recombination in the mother's own meiosis, were transmitted together. This is the signature of maternal MI nondisjunction: both homologs (heterozygous at the centromere-proximal marker) went to the same pole at meiosis I.
- If the child is A/A/C (or B/B/C) — carrying two identical copies of one maternal allele plus the paternal allele — this shows that two identical sister chromatids of a single maternal homolog were transmitted together. This is the signature of maternal MII nondisjunction (or, in some cases, an MI event with no recombination near the centromere, which can mimic an MII signature — a genuine subtlety geneticists must control for using multiple markers along the chromosome).
Empirically, when many families are examined this way, roughly two-thirds to three-quarters of trisomy-21 cases are traced to maternal MI errors, a minority to maternal MII errors, and a small fraction to paternal nondisjunction — data that both confirm the MI/MII mechanistic distinction predicted from meiotic cell biology and pin down where in gametogenesis the age-related risk actually accumulates (favoring the long MI arrest in oocytes as the culprit).
Example 2 — Predicting gamete and offspring ratios from a translocation-independent simple trisomy cross (Drosophila model). Suppose a Drosophila female is trisomic for chromosome 4 (the small autosome), genotype 4/4/4 at a recessive eye-color-influencing locus eyeless (ey), where two copies are wild-type alleles (ey⁺) and one copy is the recessive mutant allele (ey), so her genotype at this locus is ey⁺/ey⁺/ey. She is crossed to a normal diploid male homozygous recessive, ey/ey. Because she is trisomic, her meiosis must partition three copies of chromosome 4 into gametes that are normally haploid (one copy) — but trisomic individuals produce a mix of n and n+1 gametes depending on how the trivalent (or the univalent-plus-bivalent) segregates at meiosis I. Assume, as is typical for a trisomic with random segregation of the three homologs two-to-one, that gametes are produced in the ratio:
- 1/3 of gametes are n, carrying one randomly chosen chromosome 4 (either ey⁺ or ey, in proportion to how many copies of each allele exist among the three: 2 ey⁺ : 1 ey, so a random single chromosome is ey⁺ with probability 2/3 and ey with probability 1/3)
- 2/3 of gametes are n+1, carrying two of the three chromosome 4's (the possible pairs being ey⁺ey⁺, ey⁺ey, ey⁺ey, i.e., again weighted by which two of the three are picked)
Working through the n-gametes: fertilized by a normal ey sperm from the father, these give diploid offspring:
- ey⁺/ey (probability 2/3 × ... ) → wild-type phenotype
- ey/ey (probability 1/3 × ...) → mutant phenotype
So among the diploid (non-trisomic) offspring class, we expect a 2 : 1 ratio of wild-type : mutant, distinctly non-Mendelian (a normal ey⁺/ey × ey/ey diploid cross gives 1:1). This skew away from the expected 1:1 monohybrid testcross ratio is itself a diagnostic clue that the mother is trisomic rather than diploid — historically, exactly this kind of ratio distortion (in maize, by L.J. Stadler and others, and independently in Datura by Blakeslee) was used to detect and map trisomics before karyotyping was routine, since each of the extra chromosomes in a trisomic series distorts segregation ratios for genes on that particular chromosome in a characteristic way.
Common misconceptions & traps
| Misconception | Why it's wrong | |
|---|---|---|
| "Nondisjunction always happens in MI." | MII and mitotic nondisjunction also occur; MI and MII leave distinguishable centromere-marker signatures, and MII/mitotic errors matter greatly in cancer and in some human trisomies. | |
| "Aneuploidy means the DNA sequence is mutated." | The DNA sequence is normal; the problem is copy number (dosage), not sequence — aneuploidy and point mutation are different classes of genetic change entirely. | |
| "All autosomal trisomies can result in a live birth, just with a syndrome." | Most autosomal trisomies (e.g., trisomy 1, or most others besides 13, 18, 21) are lethal in utero; only a few gene-content-permissive trisomies survive to term. | |
| "Down syndrome is only caused by nondisjunction." | About 95% of trisomy 21 cases are due to nondisjunction, but ~3–4% arise from a Robertsonian [[Translocations | translocation]] carried by a parent, and ~1–2% are mosaic, arising from a post-zygotic mitotic error — these have different recurrence risks. |
| "A trisomic organism just has 'more' of everything and is stronger." | Extra chromosome dose disrupts stoichiometric balance among interacting gene products; it is a burden, not a bonus — there is no general fitness advantage to aneuploidy. | |
| "Monosomy and trisomy have symmetric severity." | Losing gene products (monosomy, ~0.5×) is typically far more damaging than gaining them (trisomy, ~1.5×), which is why autosomal monosomy is almost never seen at birth in humans while several trisomies are. |
The scientist behind it
Calvin Blackman Bridges (1889–1938) was one of the "Fly Room" scientists working under Thomas Hunt Morgan at Columbia University, alongside Alfred Sturtevant. Bridges began as an undergraduate assistant washing bottles and feeding fly stocks and rose to become one of the most meticulous and inventive experimentalists in the lab, renowned for his obsessive precision in scoring fly phenotypes and his skill with the microscope. It was Bridges who noticed and chased down the rare, anomalous "exceptional" flies that a less careful observer might have dismissed as contamination or scoring error — flies whose sex-linked inheritance pattern didn't fit the rules everyone else in the lab was busy confirming. His insistence on explaining every anomalous fly, rather than discarding it as noise, led directly to the nondisjunction discovery. Bridges went on to construct some of the first detailed cytological (chromosome) maps of Drosophila polytene chromosomes and to compile foundational genetic maps and stock catalogs that underpinned decades of subsequent Drosophila genetics.
Origins · 1 minCalvin Blackman Bridges and how this was discovered
Where this matters today
Prenatal screening and diagnosis. Noninvasive prenatal testing (NIPT) analyzes cell-free fetal DNA circulating in maternal blood to screen for trisomy 21, 18, and 13 and sex-chromosome aneuploidies with high sensitivity, largely replacing older serum-marker screening as a first-tier test; definitive diagnosis still relies on karyotyping or chromosomal microarray from chorionic villus sampling or amniocentesis.
Reproductive medicine and IVF. Preimplantation genetic testing for aneuploidy (PGT-A) screens embryos created by in vitro fertilization before transfer, since aneuploidy rates in human embryos are high (a substantial fraction of embryos, especially from older patients, are aneuploid) and are a major cause of implantation failure and miscarriage in assisted reproduction.
Oncology. Most solid tumors are aneuploid, arising from chromosomal instability driven by mitotic segregation errors (analogous mechanistically to meiotic nondisjunction — checkpoint failure, cohesin dysfunction, merotelic attachments); understanding aneuploidy mechanics informs research into why aneuploid cells can be selectively vulnerable to certain drugs (e.g., agents targeting the spindle checkpoint or proteotoxic stress pathways), a strategy under active investigation for cancer therapy.
Genetic counseling. Distinguishing free trisomy from translocation-based trisomy (as in the warning above) is essential in clinical practice, because it changes the recurrence-risk counseling given to parents for future pregnancies and can reveal a previously unsuspected balanced-translocation carrier parent who needs their own counseling and testing of other relatives.
Agriculture and plant breeding. Aneuploid and polyploid series in crops (wheat, and classic work in maize, oat, and Datura) have long been used to map genes to specific chromosomes by observing characteristic dosage-linked phenotypic changes, a forerunner of modern chromosome and genome mapping, and remains relevant to breeding programs manipulating chromosome number for trait introgression.
Ask the tutor: How do geneticists actually use centromere-linked DNA markers to prove that a specific trisomy came from the mother's meiosis I rather than meiosis II?
What is the difference between nondisjunction and aneuploidy?
Nondisjunction is the event — the mechanical failure of homologous chromosomes (at meiosis I) or sister chromatids (at meiosis II, or in mitosis) to separate properly during cell division. Aneuploidy is the outcome — an abnormal chromosome number (trisomy, 2n+1, or monosomy, 2n−1) found in a cell or organism, typically resulting when a gamete produced by nondisjunction fuses with a normal gamete at fertilization. Not all aneuploidy traces back to meiotic nondisjunction; mitotic nondisjunction after fertilization can produce mosaic aneuploidy, in which only some of an individual's cells carry the abnormal chromosome number.
Why does maternal age increase the risk of trisomy so much more than paternal age?
Human oocytes complete meiosis I only just before ovulation, but they enter meiotic prophase I and arrest there before the mother herself is born, remaining suspended for years to decades. During this prolonged arrest, cohesin proteins that hold sister chromatids and homologs together are not replenished and gradually degrade, weakening the physical tethers needed to correctly orient and separate chromosomes at meiosis I. Sperm, by contrast, are produced continuously from puberty onward through complete rounds of meiosis with no comparable multi-decade arrest, so this particular cohesin-decay mechanism does not apply to the same degree, and paternal age effects on aneuploidy are much smaller.
Is Down syndrome always caused by the same chromosomal event?
No. About 95% of cases are "free" or "regular" trisomy 21, an extra whole chromosome 21 from meiotic nondisjunction, usually maternal in origin. Roughly 3–4% arise from a Robertsonian translocation, where chromosome 21 material is attached to another acrocentric chromosome (commonly chromosome 14); this can be inherited from a phenotypically normal carrier parent and carries a substantially different, sometimes much higher, recurrence risk. About 1–2% are mosaic, arising from a mitotic nondisjunction event after fertilization, so only a fraction of the individual's cells are trisomic, often correlating with a milder phenotype.
Why are sex chromosome aneuploidies (like XXY or XXX) generally milder than autosomal trisomies?
Sex chromosome aneuploidies are buffered by X-inactivation: in humans, all but one X chromosome in any cell is transcriptionally silenced regardless of total X count, which partially normalizes gene dosage from extra X chromosomes. The Y chromosome, meanwhile, carries relatively few genes. As a result, conditions like Klinefelter syndrome (XXY) and Triple X syndrome (XXX) tend to have milder, more variable phenotypes than autosomal trisomies of comparable chromosome size, though they still carry real clinical consequences (e.g., infertility, developmental and endocrine effects in XXY).
How can nondisjunction be distinguished from a translocation using a karyotype?
A standard karyotype shows the number and banding pattern of chromosomes. In simple aneuploidy from nondisjunction, the karyotype shows an extra or missing whole chromosome of otherwise normal structure — for trisomy 21, a karyotype notation of 47,XX,+21 or 47,XY,+21. In a translocation-based case, the total chromosome count may appear normal or reduced (e.g., 46 chromosomes) because two chromosomes have fused, but one of them carries extra material from another chromosome attached to it — for a Robertsonian translocation causing Down syndrome, the notation might read 46,XX,der(14;21)(q10;q10),+21, reflecting a rearranged rather than simply extra chromosome.
Can nondisjunction happen in mitosis, and does it matter?
Yes. Mitotic nondisjunction occurs after fertilization, in a somatic cell during development, and produces a patch of aneuploid cells alongside normal cells — a condition called mosaicism. This matters clinically (mosaic trisomy 21 often produces a milder phenotype than full trisomy) and matters enormously in cancer biology, where mitotic chromosome missegregation (chromosomal instability) is extremely common in tumors and is driven by many of the same molecular failures — checkpoint defects, cohesin dysfunction, and merotelic spindle attachments — that cause meiotic nondisjunction.
How does aneuploidy relate to polyploidy?
Aneuploidy changes the number of one or a few individual chromosomes relative to the normal diploid set (2n+1, 2n−1), usually from a single nondisjunction event. Polyploidy changes the number of complete chromosome sets (3n, 4n, and so on), typically from whole-genome errors such as failure of a first mitotic division after fertilization, or fusion of an unreduced (diploid) gamete with a normal haploid gamete. Polyploidy is common and often viable in plants, where it is a major driver of speciation and crop improvement, but is essentially always lethal in humans; the mechanisms and consequences of nondisjunction versus Polyploidy are closely related but operationally distinct.